JPMorgan Chase & Co. Issues Positive Forecast for Establishment Labs (NASDAQ:ESTA) Stock Price

Establishment Labs (NASDAQ:ESTA) had its price objective raised by JPMorgan Chase & Co. from $71.00 to $80.00 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

ESTA has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday. Mizuho upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday. BTIG Research increased their price objective on shares of Establishment Labs from $70.00 to $81.00 and gave the company a “buy” rating in a report on Friday, November 14th. Canaccord Genuity Group raised their price objective on shares of Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Needham & Company LLC boosted their target price on Establishment Labs from $70.00 to $84.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus price target of $78.14.

Establishment Labs Stock Up 0.8%

ESTA opened at $74.71 on Wednesday. The stock’s 50 day moving average price is $60.41 and its 200 day moving average price is $47.30. The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10. The stock has a market cap of $2.17 billion, a P/E ratio of -26.31 and a beta of 1.01. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $78.24.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.16. The company had revenue of $53.78 million during the quarter, compared to analysts’ expectations of $52.28 million. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The company’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.59) earnings per share. As a group, research analysts predict that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC lifted its stake in Establishment Labs by 11.1% during the third quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after purchasing an additional 197,962 shares during the last quarter. Bamco Inc. NY increased its holdings in shares of Establishment Labs by 30.2% in the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after buying an additional 274,287 shares in the last quarter. Tyro Capital Management LLC increased its holdings in shares of Establishment Labs by 1.0% in the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock valued at $44,165,000 after buying an additional 10,735 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of Establishment Labs by 17.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock valued at $41,709,000 after acquiring an additional 152,299 shares during the last quarter. Finally, Mudita Advisors LLP boosted its stake in shares of Establishment Labs by 14.3% during the 3rd quarter. Mudita Advisors LLP now owns 686,764 shares of the company’s stock worth $28,150,000 after acquiring an additional 86,100 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.